期刊文献+

中老年住院良性前列腺增生患者血糖和血脂代谢异常的现状 被引量:7

下载PDF
导出
摘要 目的了解中老年良性前列腺增生(BPH)患者糖脂代谢异常现状,并探讨不同血糖、血脂代谢水平与BPH的相关性。方法选取≥50岁的BPH患者176例,所有患者均检测空腹血糖(FPG)及血脂等指标。对于未诊断2型糖尿病(T2DM)的患者,如FPG<7.0 mmol/L均口服75 g葡萄糖粉行口服葡萄糖耐量试验(OGTT);如FPG>7.0 mmol/L,隔日复查FPG。采用腹部超声测量并计算前列腺体积(PV)。采用国际前列腺症状评分(IPSS)评估下尿路症状,生活质量指数评分(QOL)评估下尿路症状对患者生活的影响程度。依据患者血糖情况分为四组,其中正常糖耐量组(NGR)49例,空腹血糖受损(IFG)组14例,糖耐量减低(IGT)组35例,T2DM组78例;其中新发糖尿病(DM)22例,原有DM 56例。结果 1176例BPH患者中DM患病率为44.32%,糖调节受损27.84%,累计糖代谢异常72.16%。若仅进行FPG检测而不进行OGTT试验,将漏诊27.84%糖调节受损患者和12.50%DM患者;此外合并高脂血症患者,NGR组有13例,IFG组3例,IGT组6例,DM组32例。2IFG组FPG显著高于NGR组、IGT组(α'<0.008);DM组FPG显著高于NGR组及IGT组(α'<0.008)。3NGR组TG显著高于IGT组(P<0.05),DM组TG显著高于IFG组、IGT组(P<0.05)。4DM组体重指数(BMI)、PV、前列腺年增长率、IPSS分值、QOL分值显著高于NGR组(α'<0.008);DM组QOL显著高于IFG组、IGT组(α'<0.008);IFG组、IGT组QOL高于NGR组(α'<0.008)。5多元线性回归分析PV与年龄(r=0.585,P<0.05)、TG(r=4.093,P<0.05)呈正相关。结论中老年BPH患者糖脂代谢异常率高,年龄、糖脂代谢紊乱是PV增大的危险因素,应常规进行OGTT试验筛查。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2015年第12期3307-3309,共3页 Chinese Journal of Gerontology
基金 河北省医学科学研究重点课题计划(ZL20140234)
  • 相关文献

参考文献4

  • 1Kim Won Tae,Yun Seok Joong,Choi Young Deuk,Kim Gi-Young,Moon Sung-Kwon,Choi Yung Hyun,Kim Isaac Yi,Kim Wun-Jae.Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. Journal of Korean medical science . 2011
  • 2H. Nandeesha,B.C. Koner,L.N. Dorairajan,S.K. Sen.Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia[J]. Clinica Chimica Acta . 2006 (1)
  • 3孟宪琴,刘伟,屈晓冰,杜万红,刘颖.糖尿病与良性前列腺增生的相关性研究[J].中国全科医学,2013,16(30):3547-3550. 被引量:17
  • 4周毅,周苏斌,王伟,姚远,杨剑文,卢启海.老年良性前列腺增生症并代谢综合征的临床相关性[J].中国老年学杂志,2012,32(22):4895-4898. 被引量:5

二级参考文献26

  • 1《中国成人血脂异常防治指南》制订联合委员会.中国成人血脂异常防治指南[M].北京:人民卫生出版社,2007:16-17.
  • 2Kasturi S,Russell S,Mcvary KT.Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia[J].Curr Urol Rep,2006;7(2):288-92.
  • 3AUA Guidelines oil management of benign prostate hyperplasia.Chapter 1:diagnose and treatment recommendations[J].J Urol,2003;170(3):530-47.
  • 4Bjorn Hildrum,Arnstein Mykletun,Torstein Hole,et al.Age specific prev-alence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program the Norwegian HUNT 2 Study[J].BMC Public Health,2007;7(2):220-3.
  • 5Ozden C,Ozdal OL,Urgancioglu G,et al.The correlation between meta-bolic syndrome and prostatic growth in patients with benign prostatic hy-perplasia[J].Eur Urol,2007;51(2):199-206.
  • 6Kristal AR,Amold KB,Schenk JM,et al.Race/ethnicity,obesity,health related behaviors and the risk of symptomatic benign prostatic hyperplasi-a:results from the prostate cancer prevention tria(lJ).J Urol,2007;177:1395-400.
  • 7Parsons JK,Cater HB,Partin AW,et al.Metabolic factors associated with benign prostatic hyperplasia[J].J Clin Endocrinol Metab,2006;91(7):2562-8.
  • 8Michel MC,Heemann U,Schumacher H,et al.Association of hypertension with symptoms of benign prostatichyperplasia[J].J Urol,2004;172:1390-3.
  • 9Meigs JB,Mohr B,Barry MJ,et al.Risk factors for clinical benign prosta-tic hyperplasia in a community based population of healthy aging men[J].Clin Epidemiol,2001;54:935-44.
  • 10Gupta A,Gupta S,Pavuk M,et al.Anthoropometric and metabolic factors and risk of benign prostat hyperplasic:a prospective cohort study of Air Force Veterans[J].Urology,2006;68:1198-205.

共引文献21

同被引文献75

  • 1孔雁萍.良性前列腺增生合并2型糖尿病患者围手术期护理[J].河北北方学院学报(自然科学版),2013,29(4):83-85. 被引量:3
  • 2那彦群,叶章群,孙光主编.中国泌尿外科疾病诊断治疗指南:人民卫生出版社,2011:417-418.
  • 3张祥华,那彦群.中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2011:9-34.
  • 4D. R. Matthews,J. P. Hosker,A. S. Rudenski,B. A. Naylor,D. F. Treacher,R. C. Turner.Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man[J]. Diabetologia . 1985 (7)
  • 5SARMA AV, ST SAUVER JL, HOLLINGSWORTH JM, et al. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men [J]. Urology, 2012,79 ( 1 ) : 102-108.
  • 6NEUHOUSER ML, SCHENK J, SONG YJ, et al. Insulin-LikeGrowth Factor-I, Insulin-Like Growth Factor Binding Protein-3 and Risk of Benign Prostate Hyperplasia in the Prostate Cancer Prevention Trial [J]. Prostate, 2008,68(13) : 1477-1486.
  • 7SAFARINF_JAD MR, SHAFIEI N, SAFARINEJAD S. Relationship of insulin-like growth factor (IGF) binding protein- 3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3 [J]. Growth Horn IGF Res, 2011,21 (3) :146-154.
  • 8NANDEESHA H, KONER BC, DORAIRAJAN LN,et al. Hyperinsulinemia and dyslipidemia in non- diabetic benign prostatic hyperplasia [J ]. Clin Chimica Acta, 2006,370 ( 1-2 ) : 89-93.
  • 9VIKRAM A, JENA GB, RAMARAO P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia [J]. Prostate, 2010,70( 1 ) : 79-89.
  • 10BERGMAN M. Pathophysiology of prediabetes and treatment implications for the preven- tion of type 2 diabetes mellitus [J ]. Endocrine, 2013,43 (3) : 504-513.

引证文献7

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部